Presentation by Tim St Pierre, Chief Scientific Researcher, Resonance Health

Validation and comparison of the diagnostic, performance of HepaFat-Scan® for assessment of liver steatosis by MRI

Share this article:

An FDA approved MRI method for measuring liver fat

Comparisons of non-invasive measures of liver steatosis using MRI methods with steatosis grading from biopsy histological sections have been presented in many peer-reviewed publications. These studies generally report the optimum thresholds for MRI measures such as proton density fat fraction (PDFF) and volumetric liver fat fraction (VLFF) that result in the optimum sensitivities and specificities for predicting the steatosis grades from biopsy in the cohort of patients studied. However, very few studies have tested the diagnostic accuracy of MRI techniques for predicting steatosis grades using predefined thresholds of PDFF or VLFF.

Tim St Pierre, Chief Scientific Researcher, Resonance Health compares the diagnostic performance of VLFF measured by the MRI method HepaFat-Scan® with the diagnostic performance reported from validation studies of other MRI techniques measuring PDFF.